| Literature DB >> 29849572 |
Changhui Qian1,2,3, Dandan Tan1,2, Xianghai Wang1,2, Lixia Li1,2, Jinkun Wen1,2, Mengjie Pan1,2, Yuanyuan Li1, Wutian Wu4,5,6, Jiasong Guo1,2,7.
Abstract
Accumulating evidences suggest that peripheral nerve injury (PNI) may initiate astrocytic responses in the central nervous system (CNS). However, the response of astrocytes in the spinal ventral horn and its potential role in nerve regeneration after PNI remain unclear. Herein, we firstly illustrated that astrocytes in the spinal ventral horn were dramatically activated in the early stage following sciatic nerve injury, and these profiles were eliminated in the chronic stage. Additionally, we found that the expression of neurotrophins, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin-3 (NT-3), also accompanied with astrocyte activation. In comparison with the irreversible transected subjects, astrocyte activation and the neurotrophic upregulation in the early stage were more drastic in case the transected nerve was rebridged immediately after injury. Furthermore, administering fluorocitrate to inhibit astrocyte activation resulted in decreased neurotrophin expression in the spinal ventral horn and delayed axonal regeneration in the nerve as well as motor function recovery. Overall, the present study indicates that peripheral nerve injury can initiate astrocyte activation accompanied with neurotrophin upregulation in the spinal ventral horn. The above responses mainly occur in the early stage of PNI and may contribute to nerve regeneration and motor function recovery.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29849572 PMCID: PMC5903197 DOI: 10.1155/2018/8561704
Source DB: PubMed Journal: Neural Plast ISSN: 1687-5443 Impact factor: 3.599
Figure 1The pattern of astrocyte activation in the spinal ventral horn after sciatic nerve injury. (a) Representative cross sections of L5 spinal cord showing GFAP-positive astrocytes and FG retrograde-labeled motoneurons that are mainly localized in the spinal ventral horn. So, a schematic diagram indicating a 300 μm × 300 μm square area was defined for further morphometric analysis. (b) GFAP/NeuN double immunostaining showing the activated astrocytes (green) and motoneurons (red) in the area as (a) defined in different groups. (c) Quantitative analysis of the number of GFAP-positive astrocytes in each measured area. (d) The number of GFAP-positive processes (measured at 15 μm away from the soma) in each astrocyte. (e-f) Immunoblot analysis of GFAP expression in the L5 spinal ventral horn. ∗P < 0.05.
Figure 2Identification of the PNI models. (a) Representative images of GAP-43 immunostained longitudinal sections to show no regenerating axon in the distal trunk of transected sciatic nerve at 28 dpi and the regenerating axons in the sutured nerves at 7 dpi and 28 dpi (∗transected sites). (b) Statistics of the sciatic functional index and (c) weight of gastrocnemius muscle assessments in the ipsilateral side of the injured nerve. ∗P < 0.05.
Figure 3Immunohistochemistry showing the expression of neurotrophins in the spinal ventral horn. (a–c) Representative images of immunostaining of BDNF, NGF, and NT3 on the samples of regenerable PNI group at 14 dpi to show the expression of neurotrophins (arrows) within astrocytes. (d–f) Statistical diagrams showing the fluorescence intensities of neurotrophins within the GFAP-positive astrocytes at different time points. ∗P < 0.05.
Figure 4Fluorocitrate treatment inhibits astrocyte activation and reduces neurotrophin expression in the spinal ventral horn and retards nerve regeneration as well as motor function recovery. (a-b) Immunohistochemistry and quantification illustrating that the number of the activated astrocytes was significantly decreased in the fluorocitrate-treated group. (c-d) Western blots revealing that the level of GFAP in the spinal ventral horn was also markedly reduced in the fluorocitrate-treated group. (e) Immunohistochemistry showing the neurotrophins (arrows) colocalizing with GFAP-positive in the spinal ventral horn. (f) Statistical diagram showing that the intensity of neurotrophin immunoreactivity in the fluorocitrate-treated group was significantly reduced. (g) GAP-43 immunochemistry showing the regenerated axons in the injured nerve (∗lesion site). (h) Statistics showing the length of regenerated axons. (i–j) Western blots and quantification showing the GAP-43 expression level in the distal segment of the injured nerve. (k) Statistics of the sciatic functional index assessments in the injured nerve. ∗P < 0.05 versus saline group, #P < 0.05 versus the standardized value of saline group.